PARP inhibitor sensitivity suggests that leukemia cells share the synthetic lethality of combined Brca1 deficiency and PARP inhibition demonstrated in mice with Brca1/Trp53-deficient mammary tumors. The gene discussed is BRCA1; the disease is breast cancer.